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Introduction 
Congenital bilateral absence of the vas deferens (CBAVD) 
is a rare condition associated with normal spermatogenesis 
and obstructive azoospermia due to lack of ducts that connect 
the epididymis to the urethra. CBAVD is usually discovered 
at adulthood during medical investigations for causes of 
clinical infertility in otherwise asymptomatic males. The 
etiology of CBAVD is not fully understood; however a well-
established connection between CBAVD and cystic fibrosis 
(CF) exists. CF is the most common life-shortening 
autosomal recessive disorder among Caucasians, and is 
characterized by recurrent pulmonary infections, elevated 
sweat chloride, pancreatic failure, hepatic insufficiency, and 
other glandular defects. App. 98% of CF males is infertile and 
exhibits CBAVD. Cystic fibrosis is caused by mutations in 
the Cystic Fibrosis Transmembrane Conductance Regulator 
(CFTR) gene that encodes an epithelial chloride-bicarbonate 
channel. CFTR mutations have also been implicated in a 
variety of pathologic conditions such as disseminated 
bronchiectasis, allergic bronchopulmonary aspergillosis, 
acute recurrent or chronic idiopathic pancreatitis, alcoholic 
chronic pancreatitis, and (as above) CBAVD. A small subset 
of males with CBAVD exhibits the disease without known 
CFTR defects. However, 80-97% of CBAVD subjects possess 
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at least one defective CFTR allele, and 50-93% of individuals 
with CBAVD carry two variants. The F508del CFTR 
mutation (deletion of phenylalanine at amino acid position 
508) is the most frequent CFTR mutation, app. 70% of patient 
carry at least one copy of this mutation. Another CFTR 
mutation at the same 508 residue - phenylalanine-to-cysteine 
replacement - has also been described, and been considered as 
a clinically silent polymorphism that does not contribute to 
CF or CBAVD. The F508del mutation decreases efficiency of 
protein folding and results in premature CFTR degradation, 
while F508C (rs74571530 previously rs1800093) is 
permissive for CFTR maturation. One in 29 Caucasian male 
in the US carries one CFTR variant but does not develop 
CBAVD. Other genetic factors must modify penetrance of 
CBAVD, however these are not yet known. Tissue growth 
factor β-1 (TGFβ-1) is a multifunctional cytokine that also 
contributes to the pathogenesis of lung fibrosis and asthma. 
Drumm et al. showed that the TGFB-1 codon 10 CC 
genotype (rs1800470 previously rs1982073) is associated 
with severe lung disease among individuals homozygous for 
CFTR mutations. A second TGFB-1 SNP in codon 25 
(rs1800471) has been implicated as a contributor to CF lung 
disease progression in some but not all studies. In addition to 
these, Darrah et al. found that endothelin receptor type A 
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(EDNRA) genotype AA at position -231 from AUG 
(rs1801708) and genotype CC in exon 8 (rs5335) were 
associated with more severe lung disease in CF patients. 
Besides the well-established connection between CFTR 
mutations and CBAVD, the role of additional genetic factors 
behind this disorder has not been studied extensively before. 
Moreover, because of the extremely large number of CFTR 
sequence alterations (1,900 published so far in the CF 
Mutation Database), the role of most defects in CBAVD has 
not been determined thus far. Therefore, in our studies, we 
have investigated the potential role of five genetic factors - 
CFTR-F508C, TGFB-1 codon 10 and 25 SNPs, EDNRA 
promoter and exon 8 SNPs – in the pathogenesis of CBAVD.  
 
Objectives 
The central hypotheses in these projects are 1) a mild 
CFTR mutation (F508C) can contribute to the CBAVD 
phenotype and 2) cystic fibrosis genetic modifiers 
influence not only the disease expression of CF but also 
impact upon the manifestation of a CFTR-related disease: 
CBAVD.  
Aim 1. Investigate the incidence and study the potential 
pathogenic role of F508C in large CF carrier, cystic fibrosis 
and CBAVD cohorts. 
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Aim 2. Examine frequencies of TGFB-1 polymorphisms 
(rs1800470 and rs1800471) and EDNRA polymorphisms 
(rs1801708 and rs5335) in CBAVD subjects. 
Aim 3. Study the hypothesis that CF modifier genes influence 
CBAVD penetrance. 
 
Materials and Methods 
Subjects in our first CBAVD study included men who had 
undergone full CFTR gene sequence analysis with the Ambry 
Test
TM
: CF at Ambry Genetics between January 2002 and 
June 2007. This group was comprised of 6,970 male patients, 
850 of whom were analyzed for CF carrier screening; 5,938 
were submitted for diagnostic testing on suspicion of CF or 
with a clinical diagnosis of CBAVD (n=182). Each individual 
tested had given written consent to have a DNA sample 
available for research studies. Genomic DNA was isolated 
from
 
blood leukocytes and DNA was assessed for quality and 
quantity by agarose gel electrophoresis. The Ambry 
Test
TM:
CF evaluates the CFTR gene by modified temporal 
temperature gradient electrophoresis analysis (mTTGE) 
followed by dye terminator DNA sequencing of suspect 
regions. The test covers all exons, at least 20 bases 5’ and 3’ 
into each intervening sequence, and select deep intronic 
mutations. Briefly, all exons as well as relevant intronic 
regions were amplified using polymerase chain reaction 
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(PCR). Prior to gel analysis, PCR products were denatured 
and slowly cooled to allow for maximal heteroduplex 
formation. For a subset of CFTR regions, DNA was mixed 
with known wild-type DNA samples to facilitate detection of 
homozygous mutations. PCR products were then processed 
for mTTGE on DCode gels. Polyacrylamide gels were 
analyzed for the presence of mutations following staining in 
ethidium-bromide and image capture under UV light using a 
GelDoc system. Gel analysis fragments were scored against 
known controls. Regions indicating the presence of a 
mutation by mTTGE were processed for dye terminator 
sequencing. Standard dye terminator cycle sequencing was 
followed by analysis on a CEQ8000 capillary electrophoresis 
sequencer.  
In our second CBAVD study, we analyzed genomic DNA 
samples from 80 CBAVD individuals and 51 healthy male 
control subjects from Europe. This included 19 patient 
samples and 20 controls from Spain, 31 CBAVD subjects and 
31 controls from Turkey, and 30 individuals with CBAVD 
from Portugal. Criteria for inclusion as a subject required 
known CFTR variants. Controls were defined as healthy 
sperm donors or other unrelated individuals with an intact vas 
deferens. The protocol was approved by the Institutional 
Review Board of Human Use at the University of Alabama at 
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Birmingham and by local Portuguese, Spanish, and Turkish 
ethical committees. All subjects have given permission to 
have his DNA sample available for research studies. A 453 bp 
region of the 5’ end of TGFB-1 gene (NT_011109) was 
amplified using 5’GAGGACCTCAGCTTTCCCTC3’ 
(forward) and 5’CTCCTTGGCGTAGTAGTCGG3’ (reverse) 
primers. This region includes both rs1800470 and rs1800471 
TGFB-1 SNPs. For the amplification of the EDNRA gene 
promoter region (Ensembl Gene ID: ENSG00000151617, 
including SNP rs1801708) the following primers 
5’GTGGAAGGTCTGGAGCTTTG3’ and 
5’TTCCCAGCTCTCGTCTTCTC3’ were used. For the 
detection of the exon 8 SNP of the EDNRA gene (rs5335), we 
used primers: 5’CTGCTGCTGTTACCAGTCCA3’ and 
5’TGACCAGTTCCCATTGAACA3’. QIAquick PCR 
Purification Kit was used prior to sequence analyses. The 
sequencing products were run according to standard protocols 
on an Applied Biosystems 3730 Genetic Analyzer with POP-
7 polymer. Sequence analyses and comparisons were 
conducted using Clustal W Multiple Sequence Alignment and 
Chromas Lite softwares.  
A 3-way Chi-Square contingency test was performed to 
ascertain the significance of F508C frequency differences 
among the three study populations. Statistical analyses were 
  
8 
performed using the VassarStats website. Since F508C was 
present in fewer than 5 subjects in two of the three study 
groups, a Monte Carlo simulation of a three categorical 
sampling distribution was run for an additional 10,000 
samples. Pairwise comparisons between the subdivided 
groups, as well as odds ratios (OR), were also calculated.  
For each TGFB-1 and EDNRA SNP, an assessment was 
performed assuming both a dominant and non-dominant 
genetic relationship with the CBAVD phenotype, as the 
precise relationships between the SNP genotype and TGFB-1 
or EDNRA activity are not known. Differences in the 
distribution of SNP genotypes were compared using χ2 
analysis. In addition, a two-sample proportion test to monitor 
differences in overall allelic frequencies was conducted 
between groups. Comparisons were performed between all 
cases and controls; and subdivided by ethnicity to evaluate for 
population specific differences. Due to the selective nature of 
the candidate genes being explored, no corrections were made 
for multiple comparisons. All statistical analyses were done 
using SPSS statistical software package. 
 
Results 
Genotype data for F508C was obtained from 850 male 
subjects undergoing complete CFTR sequence analysis for CF 
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carrier screening, as well as a group of 182 subjects with a 
clinical diagnosis of CBAVD. In addition, data from 5,938 
patients submitted for diagnostic testing on suspicion of CF 
were also analyzed. Among the 850 individuals referred for 
CF carrier screening, 3 (0.35%) subjects had the F508C 
variant without a second mutation. When CFTR from 182 
CBAVD individuals was analyzed, a total of 3 (1.65%) 
individuals were identified as carriers of F508C in addition to 
another mutation (Table 1.). In 18 specimens submitted for 
diagnostic testing on suspicion of CF, F508C was the only 
detected variant. In 5 CF individuals, the F508C variant was 
present along with a second mutation (Table 2.). 
Comparatively, the allelic frequency of F508C in the CBAVD 
population was 4.68 times higher than the CF carrier 
screening population. Detailed F508C frequency data from all 
three study groups are presented in Table 3. below. When 
comparing allelic frequencies of F508C in the group of 
patients with CBAVD to those CF patients for whom F508C 
was observed with a second CFTR mutation, F508C among 
CBAVD patients was 19.6 times more frequent. Two-way χ2 
tests revealed that the frequency of F508C was significantly 
higher in the CBAVD group than any other group (Table 3.). 
Comparison of the F508C frequencies between the CF carrier 
screen group and the group submitted for diagnostic testing 
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on suspicion of CF showed no detectable difference (χ2=0; 
p=1).  
Table 1. Genotypes of CBAVD patients with F508C. 
Patient 
# 
Mutation 
1 
Mutation 
2 
Clinical History Age 
1 F508del F508C CBAVD 39 
2 F508del F508C CBAVD, sinusitis, 
asthma 
34 
3 L206W F508C CBAVD 40 
 
Table 2. Genotypes of patients with F508C submitted for 
diagnostic testing on suspicion of CF.  
Patient 
# 
Mutation 
1 
Mutation 
2 
Clinical History Age 
1 G551D F508C Positive newborn 
screen 
>1 
mo 
2 V754M F508C Clinical suspicion 
of CF 
1 mo 
3 DeltaF508 F508C Clinical suspicion 
of CF 
24 
yrs 
4 DeltaF508 F508C Clinical suspicion 
of CF 
11 
yrs 
5 DeltaF508 F508C Clinical suspicion 
of CF 
32 
yrs 
 
In a more robust three-way comparison, the frequency of 
F508C in individuals with CBAVD was significantly 
increased relative to both the CF carrier screen group and the 
group submitted for diagnostic testing on suspicion of CF 
(χ2=6.95; p=0.031). The Monte Carlo simulation for 10,000 
replications yielded a cumulative probability of 0.0486. 
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Table 3. F508C frequencies in all study groups 
 
 
Patients 
with 
CBAVD 
(F508C 
plus 
another 
mutation) 
CF 
carrier 
screen 
(F508C 
only) 
Patients submitted for 
diagnostic testing on 
suspicion of having CF 
Total 
 
F508C plus 
another 
mutation 
F508C 
only 
Patients 
with 
F508C 
3 3 5 b 18 29 
Total 
patients 
Alleles 
182 
364 
 
850 
1,700 
 
5,938 
11,876 
 
5,938 
 11,876 
 
6,970 
13,940 
 
F508C 
allele 
frequency 
0.824% 0.176% 
0.042% 0.151% 
0.208% 
0.193% 
χ2, (p) 
 
 
2.38 
(0.073) 
21.94  
(0.002) 
5.87  
(0.023) 
 
4.01 (0.038) 
Odds 
ratio 
 4.701 4.283  
Chi square and odds ratios are shown for the group with a diagnosis 
of CBAVD compared to the CF carrier screening, patients submitted 
for diagnostic testing on suspicion of CF, or all other pooled groups 
in pairwise comparisons. P values shown are corrected for 10,000 
samples simulation.  
b Determined to carry one disease-associated CFTR mutation in 
addition to F508C. 
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In our modifier gene study, we tested whether codon 10 
and codon 25 TGFB-1 polymorphisms, or either of the two 
EDNRA gene polymorphisms might act as genetic modifiers 
of CBAVD. The EDNRA exon 8 CC allele was significantly 
more frequent in the largest matched study cohort (i.e. 
Turkish patients vs. controls 45.2% vs. 19.4%, p<0.05 by χ2- 
analysis), and between all cases vs. controls (36% vs. 15.7%, 
p<0.05). The rs1801708 SNP did not appear to influence the 
penetrance of CBAVD (p=0.22) for either Turkish or Spanish 
cases vs. controls (Table 4). 
Table 4. EDNRA genotype distributions in CBAVD 
patients and controls 
EDNRA polymorphisms Patients Controls 
Exon 8  
(rs 5335) 
 
Turkish  CC d 14 45.2% 6  19.4% 
CG 12 38.7% 20 64.5% 
GG 5 16.1% 5 16.1% 
Spanish CC 4 21.1% 2 10% 
CG 11 57.8% 13 65% 
GG 4 21.1% 5 25% 
     
Total e 50 51 
Promoter 
(rs 1801708) 
 
Turkish AA 5 16.1% 8 25.8% 
AG 18 58.1% 10 32.3% 
GG 8 25.8% 13 41.9% 
Spanish AA 0 0% 2 10% 
AG 7 36.8% 8 40% 
GG 12 63.2% 10 50% 
     
Total 50 51 
d p < 0.05 for Turkish population, χ2 analysis 
e p < 0.05 for all subjects shown, χ2 analysis 
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Studies of the rs1800470 SNP indicated a trend towards 
increased T allelic frequency in all CBAVD subjects 
compared to controls (55% vs. 45%), although none of the 
subgroup analyses indicated a significant association with 
CBAVD penetrance. With regard to TGFB-1 codon 25 SNP 
(rs1800471), there was no association with CBAVD for any 
of the analyses performed. We observed a notable increase of 
the CC allele at SNP rs 5335 in association with CBAVD 
(shown in Table 4). Detailed TGFB-1 genotype distribution 
data are listed in Table 5. 
Table 5. TGFB-1 genotype distribution in CBAVD 
patients and controls 
TGFB-1 polymorphisms Patients Controls 
Codon 10  
(rs1800470 
previously 
rs1982073) 
 
Turkish  CC 8 25.8% 13 41.9% 
CT 12 38.7% 8 25.8% 
TT 11 35.5% 10 32.3% 
Spanish CC 4 21.1% 6 30% 
CT 6 31.6% 10 50% 
TT 9 47.4% 4 20% 
     
Total 50 51 
Codon 25 
(rs1800471) 
 
Turkish GG 26 83.9% 28 90.3% 
GC 5 16.1% 3 9.7% 
CC 0 0% 0 0% 
Spanish GG 19 100% 17 85% 
GC 0 0% 3 15% 
CC 0 0% 0 0% 
     
Total 50 51 
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Conclusions 
 The F508C-CFTR mutation frequency was significantly 
elevated among subjects with CBAVD compared to either CF 
carriers or CF patients. Based on our results, F508C is 
causative for both CBAVD and CF when present with a 
second CFTR mutation. However, because of the significantly 
elevated frequency of the mutation among CBAVD subjects, 
we can conclude that F508C (together with an additional 
CFTR gene defect) is more likely to lead to CBAVD than CF. 
 TGFB-1 polymorphisms rs 1800470 and rs 1800471 do not 
affect CBAVD penetrance. Thus, TGFB-1 - a known genetic 
modifier of cystic fibrosis lung disease – did not influence 
CBAVD in our subject groups. 
 The EDNRA exon 8 CC allele was significantly more 
prevalent among CBAVD patients and controls from Turkey 
and between all cases vs. controls. The EDNRA promoter 
SNP (rs1801708) did not influence the CBAVD phenotype in 
our study groups. Based on these, endothelin receptor type A 
gene serves as a CBAVD specific genetic modifier. 
These studies provide important new information regarding 
the genetic factors that contribute to CBAVD. Large, 
multicenter studies will be needed to clarify the role of other, 
classically non-disease-associated CFTR mutations and 
putative modifier genes in CBAVD.  
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